Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent

NCT05465031 is registered in ClinicalTrials.gov with Silesian Centre for Heart Diseases as lead sponsor.

NCT NCT05465031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05465031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent
Lead sponsor
Silesian Centre for Heart Diseases
Phase
Phase 4
Overall status
Recruiting
Start date
April 17, 2024
Completion date
February 28, 2029
Enrollment
600 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

angiotensin ii type 1 receptor blockers, angiotensin receptor antagonists, antihypertensive agents, breast cancer, breast diseases, cancer therapy-related cardiac dysfunction, cancer, therapy-related, cardiac toxicity, cardiotoxicity, heart failure, molecular mechanisms of pharmacological action, neoplasm, breast, sacubitril/valsartan